Tesamorelin 5mg

Tesamorelin Peptide is a synthetic analogue of growth hormone–releasing hormone (GHRH) that stimulates the pituitary gland to secrete endogenous growth hormone. It is primarily approved for reducing visceral adipose tissue in HIV-associated lipodystrophy. Tesamorelin enhances lipolysis, improves body composition, and has shown potential benefits in metabolic regulation and neurocognitive function.

Introduction

Tesamorelin emerged as an important therapeutic innovation in the field of endocrinology and metabolic disorders. Initially developed to address the challenges of abnormal fat distribution in individuals living with HIV, it has since drawn wider interest for its effects on body composition, metabolic health, and even cognitive outcomes. In patients with HIV, antiretroviral therapy has been associated with lipodystrophy, particularly the excessive buildup of visceral adipose tissue (VAT). This type of fat accumulation is not only cosmetically distressing but also increases the risk of cardiovascular disease, insulin resistance, and hepatic dysfunction. Traditional strategies such as exercise and dietary modification offer limited results in reducing VAT, creating the need for more targeted approaches. Tesamorelin became a valuable option by showing the ability to selectively decrease VAT while preserving subcutaneous fat, thereby improving both health outcomes and quality of life. Beyond its role in fat redistribution, tesamorelin has sparked research interest in its potential influence on neurocognitive health. Evidence suggests that individuals with HIV often experience accelerated cognitive decline, partly due to chronic inflammation and metabolic disturbances. Tesamorelin treatment has been linked with improvements in certain aspects of memory and executive function, likely related to enhanced growth hormone and insulin-like growth factor-1 activity, which are known to support neuronal survival and plasticity. This has raised the possibility that tesamorelin could serve as a therapeutic candidate in broader populations at risk of dementia and age-related cognitive decline. Additionally, recent investigations have explored its impact on liver health. Nonalcoholic fatty liver disease (NAFLD) and steatohepatitis are increasingly recognized complications in people with metabolic syndrome and HIV. Tesamorelin has been shown to reduce hepatic fat content, highlighting its potential role in managing these conditions where no specific pharmacological therapy currently exists. Overall, tesamorelin represents more than just a treatment for HIV-associated lipodystrophy. Its wider implications in metabolic regulation, neuroprotection, and liver health suggest a promising future for this peptide in multiple areas of medicine. Ongoing clinical trials continue to refine its therapeutic profile and long-term safety, paving the way for expanded indications beyond its initial approval.

 Mechanism of action

After subcutaneous administration, it binds to GHRH receptors located on the anterior pituitary somatotroph cells. This receptor activation stimulates the cyclic AMP (cAMP) and protein kinase A (PKA) signaling pathways, which in turn enhance transcription and secretion of growth hormone (GH) in a pulsatile and physiologically regulated manner. The released GH acts on multiple tissues, most importantly the liver, where it stimulates the production of insulin-like growth factor-1 (IGF-1). IGF-1 then circulates systemically and mediates many of the anabolic and metabolic effects of GH. Together, GH and IGF-1 promote lipolysis, increase protein synthesis, and regulate glucose and lipid metabolism. In patients with HIV-associated lipodystrophy, tesamorelin primarily reduces visceral adipose tissue (VAT) by stimulating breakdown of triglycerides into free fatty acids, while sparing subcutaneous fat stores. The selective reduction in VAT helps improve body composition and lowers cardiometabolic risks. Additionally, by restoring a more physiological GH–IGF-1 axis, tesamorelin may exert beneficial effects on the brain, liver, and muscle. Experimental studies suggest that IGF-1 supports neuronal survival and synaptic plasticity, which could underlie cognitive benefits seen in some patients. In the liver, tesamorelin has been shown to reduce hepatic fat accumulation, offering a potential therapeutic pathway in fatty liver disease.

Structure

  Sequence: Unk-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-GIn-Leu-Ser-Ala-Arg-Lys-Leu-Leu-GIn-Asp-Ile-Met-Ser-Arg-GIn-GIn-Gly-Glu-Ser-Asn-GIn-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu Molecular Formula: C223H₃₇₀N₇₂O₆₉S Molecular Weight: 5195.908 g/mol PubChem CID: 44147413 CAS Number: 901758-09-6

Research

Role of tesamorelin in lypodysrophy

Tesamorelin plays a clinically significant role in managing HIV-associated lipodystrophy by targeting abnormal visceral adipose tissue (VAT), which contributes to metabolic dysfunction and altered body image in patients undergoing long-term antiretroviral therapy. Its mechanism involves stimulating endogenous growth hormone release, thereby increasing IGF-1 levels, which preferentially reduces VAT without significantly affecting subcutaneous fat (1). Clinical trials provide strong evidence for its efficacy. A 26-week randomized controlled study demonstrated that daily 2 mg tesamorelin reduced VAT by approximately 15% compared to an increase in the placebo group, alongside improvements in triglycerides and cholesterol ratios (2). Similarly, pooled analyses from phase 3 trials confirmed that these reductions in VAT were sustained at 52 weeks while preserving peripheral and limb fat (3). These outcomes highlight tesamorelin as an effective option for improving both metabolic parameters and patient-reported body image. Beyond its effects on visceral fat, tesamorelin has shown promise in reducing hepatic fat content, which may have implications for patients with nonalcoholic fatty liver disease, particularly in those living with HIV (4). However, further research is needed to confirm its long-term impact on liver health and cardiovascular outcomes. The drug is approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of excess abdominal fat in HIV-infected adults with lipodystrophy (5). The recommended dose is 2 mg subcutaneously once daily. While generally well tolerated, adverse effects include injection-site reactions, arthralgia, edema, and transient increases in IGF-1 (5). Glucose intolerance has also been observed, necessitating regular glycemic monitoring in patients with risk factors for diabetes (6). In summary, tesamorelin represents a validated, evidence-based therapy for reducing VAT in HIV-associated lipodystrophy, improving both physical and psychological outcomes, though long-term safety considerations warrant ongoing monitoring (2,3,5).

Tesamorelin and cardiovascular outcomes

It has gained attention for its potential role in reducing cardiovascular risk among people living with HIV, primarily through its effects on visceral adiposity and related cardiometabolic parameters. Excess visceral fat is strongly linked to increased arterial inflammation, dyslipidemia, and insulin resistance, all of which contribute to heightened cardiovascular disease (CVD) risk in this population (7). By selectively decreasing visceral adipose tissue, tesamorelin may indirectly mitigate these mechanisms and improve vascular health (2). Clinical research supports this cardioprotective potential. A study using positron emission tomography/computed tomography (PET/CT) demonstrated that tesamorelin treatment significantly reduced arterial inflammation, an established marker of atherosclerotic risk, in HIV-infected patients with abdominal obesity (8). Moreover, reductions in triglycerides and improvements in the total-to-HDL cholesterol ratio observed in phase 3 trials suggest an additional benefit in lowering atherogenic lipid burden (9). Beyond lipid metabolism, tesamorelin’s impact on inflammatory and fibrotic pathways has also been explored. Evidence indicates that by lowering visceral fat, it may decrease pro-inflammatory cytokine activity and improve endothelial function, which are critical in preventing plaque formation and vascular stiffening (4). While these findings are promising, long-term studies are still needed to determine whether tesamorelin translates into reduced incidence of myocardial infarction, stroke, or cardiovascular mortality. In summary, tesamorelin shows potential as a therapeutic adjunct in reducing cardiovascular risk among HIV-infected individuals with excess visceral fat by lowering arterial inflammation, improving lipid profiles, and modulating inflammatory pathways (2,4,9). However, definitive evidence on long-term cardiovascular outcomes remains to be established.

Role of tesamorelin in perepheral nerve damage

It has also been investigated for its potential neuroprotective effects, particularly in relation to peripheral nerve damage. Growth hormone (GH) and insulin-like growth factor-1 (IGF-1), which are increased by tesamorelin administration, play important roles in neuronal survival, axonal regeneration, and remyelination (10). Experimental evidence indicates that IGF-1 supports Schwann cell function and enhances nerve repair following injury, suggesting that tesamorelin could indirectly facilitate peripheral nerve recovery through GH/IGF-1–mediated pathways (11). In animal studies, GH-releasing factor analogues have been shown to accelerate nerve regeneration, improve conduction velocity, and reduce neuropathic symptoms, effects largely attributed to IGF-1–induced neurotrophic signaling (12). Although direct clinical trials with tesamorelin in peripheral neuropathy are limited, these mechanistic insights provide a rationale for its potential therapeutic application in conditions such as HIV-associated neuropathy, diabetic neuropathy, or trauma-induced nerve injury (13). Furthermore, IGF-1 has demonstrated the ability to reduce oxidative stress and apoptosis in peripheral nerves, thereby preserving neuronal integrity and functional recovery (14). This highlights tesamorelin’s possible role as an adjunct therapy to promote neural repair, though further targeted clinical research is needed to validate its efficacy in humans.

Growth hormone deficiency and HIV

Growth hormone (GH) deficiency is increasingly recognized in people living with HIV, especially those with central adiposity and metabolic complications. Chronic HIV infection and long-term antiretroviral therapy are associated with impaired hypothalamic–pituitary function, reduced spontaneous GH secretion, and lower insulin-like growth factor-1 (IGF-1) levels (15). This relative deficiency contributes to visceral fat accumulation, dyslipidemia, and insulin resistance, resembling the metabolic profile of non-HIV GH-deficient patients (16). Studies have shown that HIV-infected individuals with lipodystrophy exhibit blunted GH responses to stimulation tests, correlating with higher visceral adipose tissue and markers of cardiovascular risk (17). Additionally, lower GH activity has been linked to increased arterial inflammation and endothelial dysfunction, further elevating cardiometabolic burden (18). Recognition of this dysfunction has led to clinical interest in GH-releasing agents such as tesamorelin, which restore physiological GH pulsatility and improve body composition without excessive GH exposure (19).

Role of tesamorelin in dementia

Tesamorelin has been explored for its potential neurocognitive benefits, particularly in the context of dementia risk and brain aging. Beyond its effects on body composition, tesamorelin stimulates endogenous growth hormone release, leading to increased insulin-like growth factor-1 (IGF-1), a neurotrophic factor known to support synaptic plasticity, neuronal survival, and cognitive performance (20). Since reduced GH/IGF-1 signaling has been associated with age-related cognitive decline and neurodegenerative processes, tesamorelin may indirectly mitigate mechanisms contributing to dementia (21). In clinical research, patients with HIV and excess visceral adiposity treated with tesamorelin demonstrated preservation of white matter integrity and improved cognitive processing speed compared to placebo, suggesting a role in protecting neural networks vulnerable to neurodegeneration (22). Neuroimaging studies further indicated that tesamorelin was associated with reduced brain atrophy in regions linked to memory and executive function, providing biological plausibility for its potential role in slowing dementia progression (23). Additionally, IGF-1 elevation induced by tesamorelin may reduce oxidative stress, neuroinflammation, and β-amyloid accumulation, processes central to Alzheimer’s disease pathology (24). While these findings are promising, large-scale randomized controlled trials are still needed to determine whether tesamorelin can directly prevent or delay dementia in high-risk populations. In summary, tesamorelin may contribute to dementia prevention by enhancing GH/IGF-1 signaling, preserving brain structure, and improving neurocognitive outcomes in vulnerable individuals, although its role remains investigational (22–24).  

References

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. N Engl J Med. 2007;357:2359–2370.
2. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone–releasing factor analogue, in HIV-infected patients with excess abdominal fat: pooled analysis of phase 3 trials. J Clin Endocrinol Metab. 2010;95(9):4291–4304.
3. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389.
4. Stanley TL, Grinspoon SK. Effects of tesamorelin on visceral fat, liver fat, and cardiometabolic risk factors in HIV-infected patients with abdominal fat accumulation. Future Virol. 2015;10(3):229–237.
5. S. Food and Drug Administration. Egrifta (tesamorelin) NDA and approval documents; 2010. Available from: https://www.accessdata.fda.gov
6. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2018.
7. Grinspoon SK. Cardiovascular risk in HIV: does tesamorelin reduce risk by reducing visceral fat? Curr Opin HIV AIDS. 2014;9(4):294–301.
8. Lo J, You SM, Liebau J, et al. Effects of tesamorelin on arterial inflammation in HIV. J Clin Endocrinol Metab. 2015;100(9):3382–3389.
9. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients: a randomized clinical trial. JAMA. 2014;312(4):380–389.
10. Sonntag WE, Ramsey M, Carter CS. Growth hormone and IGF-1 in the brain: mechanisms for neuroprotection. Mech Ageing Dev. 2005;126(2):201–207.
11. Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med. 1999;107(2B):34S–42S.
12. Håkansson J, Kanje M. Insulin-like growth factor I (IGF-I) stimulates regeneration of the rat sciatic nerve. Brain Res. 1990;486(2):396–398.
13. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist. 2008;14(1):23–29.
14. Cheng HL, Feldman EL. IGF-I promotes peripheral nervous system myelination. Ann N Y Acad Sci. 1997;825:317–325.
15. Stanley TL, Grinspoon SK. Body composition and metabolic changes in HIV-infected patients. J Infect Dis. 2012;205(Suppl 3):S383–90.
16. Barkan AL, Dimaraki EV. Growth hormone deficiency: diagnosis and clinical management. Endocrinol Metab Clin North Am. 2003;32(1):171–86.
17. Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S. Metabolic regulation of growth hormone in HIV-lipodystrophy. J Clin Endocrinol Metab. 2005;90(9):5595–603.
18. Lo J, You SM, Liebau J, et al. Reduced growth hormone secretion relates to vascular inflammation in HIV-infected patients. J Clin Endocrinol Metab. 2010;95(9):4465–74.
19. Falutz J, Mamputu JC, Potvin D, et al. Tesamorelin and metabolic risk in HIV-associated abdominal fat accumulation. J Clin Endocrinol Metab. 2010;95(9):4291–304.
20. Sonntag WE, Ramsey M, Carter CS. Growth hormone and IGF-1 in the brain: mechanisms for neuroprotection. Mech Ageing Dev. 2005;126(2):201–7.
21. Aleman A, Torres-Alemán I. Neuroendocrine basis of brain aging and neurodegeneration. Prog Neurobiol. 2009;89(1):1–19.
22. Fitch KV, Anderson EJ, Hubbard JL, et al. Effects of tesamorelin on cognition and white matter in HIV-infected patients with abdominal fat accumulation. AIDS. 2019;33(3):531–9.
23. Cook JA, Johnson SC, Erlandson KM, et al. Neuroimaging correlates of tesamorelin treatment in HIV-associated neurocognitive disorder. J Acquir Immune Defic Syndr. 2020;83(5):520–8.
24. Carro E, Torres-Alemán I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer’s disease. Eur J Pharmacol. 2004;490(1–3):127–33.

Ingredients: Tesamorelin (synthetic peptide) Storage: Store in a cool, dry place. Keep refrigerated to maintain potency. Caution: Use under the supervision of a qualified healthcare professional. Not intended for use by individuals under 18 years of age. Note: Results may vary based on individual response and adherence to usage recommendations. FAQs: How does Tesamorelin work? Tesamorelin stimulates the release of growth hormone, which aids in fat metabolism and promotes lean muscle growth. What are the potential side effects?

Common side effects may include injection site reactions, headache, and increased appetite. Consult your healthcare provider for a comprehensive list of potential side effects. Can Tesamorelin be used for weight management? Yes, Tesamorelin is particularly effective for those looking to manage weight by reducing body fat and improving metabolic function. Is a prescription required? Yes, Tesamorelin should be used under the guidance of a healthcare professional and typically requires a prescription.